Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the first patient has been dosed in a Phase 1 study evaluating the tolerability and pharmacokinetics of MDMA-like compounds, including MDA and prodrugs Lys-MDMA and Lys-MDA, against a placebo. The trial at University Hospital Basel aims to assess acute effects in 24 healthy subjects using various dosages. Key measures include subjective effects and plasma levels over 18 months. This investigation may enhance understanding of MDMA-related therapies, supporting MindMed's ongoing drug development for brain health disorders.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced on Sept. 14, 2022, that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as advised by The Nasdaq Stock Market LLC. This compliance follows the completion of a reverse share split and enables the company to meet important corporate objectives, such as enhanced visibility in the investment community and increased liquidity of its shares. The matter is now considered closed by Nasdaq.
MindMed announced positive clinical data for its product candidate MM-120, targeting Generalized Anxiety Disorder (GAD), from a study at University Hospital Basel. The peer-reviewed publication outlines how LSD produced significant, long-lasting reductions in anxiety and depression symptoms in patients. The ongoing Phase 2b trial aims to enroll 200 participants. MindMed retains all clinical data and manufacturing rights for MM-120, which offers a unique commercial opportunity. The company emphasizes its robust intellectual property strategy, with multiple pending patents extending protection into the 2040s.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, with its presentation accessible from 7:00 a.m. ET on September 12, 2022. As a clinical stage biopharmaceutical company, MindMed focuses on developing innovative treatments for brain health disorders. The company aims to enhance patient outcomes through its drug candidates targeting serotonin, dopamine, and acetylcholine systems. A replay of the presentation will be available in the 'News & Media' section of MindMed's website.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced a 1-for-15 reverse share split effective August 26, 2022. Common shares will begin trading on a split-adjusted basis on August 29, 2022. This move aims to meet Nasdaq's minimum bid price requirement and enhance the Company’s flexibility for future business needs. No fractional shares will be issued post-split; shares below half will be canceled while those at least half will convert to whole shares. The Company continues to trade under the symbols MNMD and MMED, with necessary adjustments made to outstanding options and warrants.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the first patient dosing in its Phase 2b trial of MM-120, a therapeutic form of LSD, targeting Generalized Anxiety Disorder (GAD). This trial is the largest of its kind for LSD, enrolling 200 participants to assess anxiety symptom reduction four weeks post-dosing. Positive topline data from previous studies supports the trial's potential. The results will influence future Phase 3 trials, aiming to deliver innovative treatments for GAD.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal as independent members of its Board of Directors, effective August 11, 2022. Their extensive experience in life sciences and product development is expected to aid MindMed in advancing its product candidates aimed at treating brain health disorders. Dr. Bruhn, formerly of Tiaki Therapeutics, and Dr. Crystal, CEO of Opiant Pharmaceuticals, bring significant expertise to the board. The company also announced Dr. Halperin Wernli's retirement from the board while continuing her role as President.
Mind Medicine Inc. (NASDAQ: MNMD) reported its Q2 2022 financial results, highlighting the advancement of its Phase 2b dose-optimization trial for MM-120, targeting generalized anxiety disorder (GAD). The company announced positive safety results for MM-110, aimed at opioid withdrawal. As of June 30, 2022, cash and equivalents stood at $105.7 million, adequate to support operations into 2024. The net loss for Q2 2022 was $17.1 million, significantly reduced from $44.5 million in Q2 2021. Leadership changes were notable, including the appointment of Schond L. Greenway as CFO and two new independent board members.
On August 11, 2022, FCM MM Holdings, LLC, led by co-founder Dr. Scott Freeman, urged Mind Medicine (NASDAQ:MNMD) to adopt a new strategic plan. The proposals include a focus on core drugs MM-110 (18-MC) and MM-120 (LSD), reducing annual cash burn from $45 million to under $25 million, and halting the at-the-money equity offering. FCM believes these changes could expedite MM-120's market entry from eight years to four. With 5.6% of MindMed's shares, FCM is committed to enhancing shareholder value.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced a 1-for-15 reverse share split, aimed at meeting Nasdaq's minimum bid price requirement and facilitating future business needs. Post-split, approximately 28.4 million shares will be outstanding, with trading set to begin on August 29, 2022. Existing warrants and options will be adjusted correspondingly. Shareholders will not need to take action for holdings via brokers, while those with physical certificates will receive further instructions from Computershare. The company's focus remains on developing treatments for brain health disorders.
